Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Published on December 23, 2025
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retinal diseases, has announced financial results for its fiscal year 2025. The company reported $1.4 million in revenue for the fiscal year ended September 30, 2025, as well as a net loss of $62.4 million. This compares with a net loss of $75.4 million and no revenue for the prior year. The company noted that both losses were “attributable to common stockholders.”
Continue reading on website
Other news

Stanton Optical Opens 13th Location in South Carolina

December 23, 2025
CHARLESTON, S.C.—Stanton Optical, a leading retail brand under Now Optics, recently announced the opening of its newest location in Charleston, S.C. The opening marks Stanton Optical’s 13th location in South Carolina, the company advised. “Stanton Optical was built with one goal in mind: to make eyecare easy,” said Lukana Justin, chief marketing officer. “Everything we do—from same-day service to

Safilo Renews Global Eyewear Licensing Agreement With Pierre Cardin, Concludes Shares Purchase Program

December 23, 2025
PADUA, Italy and PARIS—Safilo Group, (SFL:MI) a leader in prescription frames, sunglasses, outdoor eyewear, goggles, and helmets, and Pierre Cardin, the historic Parisian fashion house, have announced the renewal of their global licensing agreement for the design, manufacturing and distribution of prescription frames and sunglasses under the Pierre Cardin brand. This renewal will run until 2031, t